HPV-Vac-S: Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India
Study Details
Study Description
Brief Summary
This project aims is to monitor the effectiveness of HPV vaccination in real-word conditions, at least 7 years after initiation of HPV vaccination in Sikkim. This study would give an opportunity to provide rapid feedback to the Indian public health authorities about the impact of the HPV vaccine.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The investigators would like to estimate the prevalence of HPV infections based on cervical samples collected from the Sikkimese women aged 18 to 22 years at baseline (i.e. when the study participants are expected to have no benefit of vaccination) and seven years after the launch of the HPV vaccination programme, by which time the initial vaccinated cohorts will be aged 18 to 22 years and many of them will be sexually active. If the vaccination programme continues with the current high coverage rate, the cohort of women in the second age group are expected to be protected due to herd immunity, irrespective of whether any individual woman receives the vaccine or not. Overall effectiveness to protect women aged 18-22 years against targeted and non-targeted HPV infections will be monitored through repeated cervical sample -based surveys.
Study Design
Outcome Measures
Primary Outcome Measures
- The reduction in the point prevalence of genotype-specific HPV infection in women within 7 years of initiation of HPV vaccination compared to that at baseline [7 years]
The investigators will estimate difference in the prevalence of genotype-specific HPV infection based on cervical samples collected from the married women aged 18 to 22 years at baseline (in the year 2020-21) and again in the year 2025-26 (seven years after the initiation of the HPV vaccination program).
- The difference in the point prevalence of chlamydia trachomatis infection in women within 7 years of initiation of HPV vaccination compared to that at baseline [7 years]
The investigators will estimate difference in the prevalence of chlamydia trachomatis infection based on cervical samples collected from the married women aged 18 to 22 years at baseline (in the year 2020-21) and again in the year 2025-26 (seven years after the initiation of the HPV vaccination program). The estimate will allow the investigators to understand any change in the background risk of sexually transmitted infection in the population over time.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women aged 18 to 22 years, resident of Sikkim and married.
-
Pregnancy will not be considered as exclusion criteria.
-
Sample collection should be avoided during active menstruation.
Exclusion Criteria:
-
Women who do not provide written consent
-
Women who are not able to cooperate in collection of cervical cell sample or respond to questions due to any acute or severe mental and physical illnesses.
-
Women who had undergone hysterectomy.
-
Vaccinated in research project
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Sikkim Manipal Hospital | Gangtok | Sikkim | India | 737107 |
Sponsors and Collaborators
- International Agency for Research on Cancer
- Department of Health and Family welfare, Government of Sikkim
- Sikkim Manipal Institute
- Rajiv Gandhi Centre for Biotechnology
Investigators
- Principal Investigator: Yogesh Verma, MD, Sikkim Manipal Inst., Sikkim, India
- Principal Investigator: Phumzay Denzongpa, MD, Dept of H & FW, Govt. of Sikkim, India
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SMIMS/IEC/C/2020-09